INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Alopecia Areata (AA) Case Study

Indero

Indero

Team of Experts

Author picture

Outcomes

  • Innovaderm’s outstanding support on this alopecia areata study resulted in a rapid increase in enrollment rates and the successful management of this trial

Study Characteristics

  • Study Phase: II
  • Patient Population: Alopecia Areata
  • IP Route of Administration: Systemic
  • Sites distribution: 12 sites (CAD-USA)
  • Complex study procedures: Ophthalmology and Pulmonary function tests

Study Challenges and Solutions

Challenge 1: Site Engagement

Withdrawal of sites prior to / during SIV due to the complexity of the study

Solutions

  • More robust FQ and discussions during SQV ensured PI/sites had a clear understanding of the logistical needs to implement the study, as well as required resources

Outcome

  • Decrease in withdrawal of sites

Challenge 2: Recruitment

  • Recruitment rates are below expectations. Sites in need of better support

Solutions

  • Conducted frequent 1:1 calls and follow-ups with sites to review recruitment plans
  • Assisted with extensive tracking of referrals,  follow through and outcomes
  • Shared other sites’ practices on effective local recruitment initiatives

Outcome

  • Renewed efforts in recruiting led to screening activity increased within 2 weeks of the 1:1 site calls

Challenge 3: Central Laboratory

  • Over the holiday period, significant issues with samples were observed incl. shipping problems experienced by the Central Lab’s vendor

Solutions

  • Re-trained sites on best practices for processing samples
  • Increased sample stability
  • PM engaged in frequent communications with lab to proactively discuss possible delays in shipping

Outcome

  • >50% reduction in related issues regarding samples exceeding stability or being inadequate for processing

Key Success Factors & Strategies

  • Bi-weekly calls between CRAs & sites to focus on recruitment
  • Implemented 1:1 site booster calls to discuss specific challenges
SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.